

Regulatory fees, applicable from the 15th of June 2012

Referring to the Norwegian legislation, "Forskrift om legemidler" of 22. December 1999 § 15-3, the fees are being updated by the 2012.06.15

The Norwegian Medicines Agency will invoice the fee on the basis of received application. Please note that we invoice the company who submits the application, should no other receiver be stated in the cover letter. Reference, such as PO-number, must be stated in the cover letter. Payment is due at the latest within 30 days from date of invoice.

In specific cases the Norwegian medicines Agency may waive the required fee.

The figures are in Norwegian "kroner" (NOK).

National		
	Human	Veterinary
Complete dossier/well-established use/fixed combinations, Art. 8(3)/10a/10b/12(3)/13a/13b	415000	210000
Hybrid and biosimilar, Art. 10(3)/10(4)/13(3)/13(4)	180000	110000
Generic /Informed concent, Art. 10 (1)/10c/13(1)/13c	160000	55000
Additional formulations and strengths applied at the same time	100000	50000
Annex I-applications except new formulations/strengths Veterinary : except change or addition of, food producing animals ¹⁾	90000	75000
Annex I :New formulations/strengths (line extensions) Veterinary : Within the same target species ¹⁾	110000	55000
Annex I :Change or addition of, new food producing animal(s) ¹⁾		85000
Variation Type IB which leads to changes in the SmPC, PL and labeling ^{2),3)}	9000	9000
Variation Type II; change in therapeutic indication ^{2),3),7)} Veterinary: Within the same target species	85000	55000
Variation Type II; change in posology ^{2),3),7)} Veterinary: Within the same target species	85000	55000
Change or addition of, new non- food producing animal(s) ¹⁾		70000
Change in withdrawal periode		25000
Variation Type II; change in legal status (prescription/non-prescription) ^{2),3)}	85000	85000
Other variation Type II ^{2),3)}	13000	13000
Other variation Type II – linguistic changes ⁹⁾	2000	2000
Renewals ⁴⁾	45000	20000

Products for disinfection		
For health care use	10000	
For use at aquacultur sites		30000
Parallell import		
Marketing Authorisation Application	20000	20000
Renewals, ⁴⁾	20000	20000
Traditional herbal medicinal products		
Marketing Authorisation Applications -with monography	25000	
Marketing Athorisation Applications - without monography	85000	
Variation Type II, change in therapeutic indication ^{2),3),7)}	25000	
Variation Type II; change in posology ^{2),3),7)}	25000	
Variation Type IB which leads to changes in the SmPC, PL and labeling ^{2),3)}	9000	
Other variation Type II ^{2),3)}	13000	
Renewals ⁴⁾	25000	
Natural remedies		
Marketing Authorisation Applications	100000	
Clinical trials (investigators initiated trials is free)		
Clinical trials Applications	10000	10000
Variations (Substantial amendments)	5000	5000

MRP for which Norway is RMS		
	Human	Veterinary
Agreement on RMS-ship	50000	50000
Initiating MRP ⁸⁾	100000	80000
Repeat use	100000	80000
Annex I-applications except new formulations/strengths Veterinary : except change or addition of, food producing animals ¹⁾	110000	75000
Annex I ¹⁾ : New formulations/strengths (line extensions) Veterinary: Within the same target species	125000	55000
Annex I :Change or addition of,new food producing animal(s) ¹⁾		85000

Variation Type IB which leads to changes in the SmPC, PL and labelling ²⁾³⁾	12000	12000
Variation type II; change in therapeutic indication ^{2), 3)} Veterinary: Within the same target species	90000	70000
Variation type II; change in posology ^{2), 3),7)} Veterinary: Within the same target species	90000	70000
Change or addition of, new non- food producing animal(s) ¹⁾		80000
Change in withdrawal periode		25000
Other variation Type II ^{2),3)}	18000	18000
Worksharing, change in therapeutic indication ^{6),7)}	90000	90000
Worksharing, change in posology ^{6),7)}	90000	90000
Worksharing Type IB which leads to changes in the SmPC, PL and labelling ²⁾³⁾⁶⁾	13000	13000
Worksharing other variationsType II ⁶⁾	13000	13000
Renewals ⁴⁾	45000	20000
Marketing Authorisation Application -traditional herbal medicinal products, with monography	85000	
Traditional herbal medicinal products		
Variation Type IB which leads to changes in the SmPC, PL and labeling ^{2),3)}	9000	
Variation Type II ^{2),3)}	13000	
Renewals ⁴⁾	25000	
MRP where Norway is CMS		
	Human	Veterinary
Complete dossier/well-established use/fixed combinations, Art. 8(3)/10a/10b/12(3)/13a/13b	155000	75000
Hybrid and biosimilar, Art. 10(3)/10(4)/13(3)/13(4)	125000	55000
Generic /Informed concent, Art. 10 (1)/10c/13(1)/13c	110000	55000
Additional formulations and strengths applied at the same time	100000	50000
Annex I-applications except new formulations/strengths Veterinary : except change or addition of, food producing animals ¹⁾	100000	50000
Annex I ¹⁾ : New formulations/strengths (line extensions) Veterinary: Within the same target species	110000	55000
Annex I :Change or addition of new food producing animal(s) ¹⁾		60000
Variation Type IB which leads to changes in the SmPC, PL and labelling	9000	9000

Variation type II; change in therapeutic indication ^{2), 3)} Veterinary: Within the same target species	45000	35000
Variation type II; change in posology ^{2), 3), 7)} Veterinary: Within the same target species	45000	35000
Change or addition of, new non- food producing animal(s) ¹⁾		40000
Change in withdrawal periode		12000
Other variation Type II ^{2), 3)}	13000	13000
Worksharing, change in therapeutic indication ⁶⁾	45000	45000
Worksharing, change in posology ^{6), 7)}	45000	45000
Worksharing Type IB which leads to changes in the SmPC, PL and labelling ²⁾³⁾⁶⁾	13000	13000
Worksharing other variations Type II ⁶⁾	13000	13000
Renewals ⁴⁾	45000	20000
Marketing Authorisation Application -traditional herbal medicinal products, with monography	20000	
Traditional herbal medicinal products		
Variation Type IB which leads to changes in the SmPC, PL and labeling ^{2), 3)}	5000	
Variation Type II ^{2), 3)}	7000	
Renewals ⁴⁾	15000	

DCP for which Norway is RMS		
	Human	Veterinary
Agreement on RMS-ship	50000	50000
Complete dossier/well-established use/fixed combinations, Art. 8(3)/10a/10b/12(3)/13a/13b	370000	170000
Hybrid and biosimilar, Art. 10(3)/10(4)/13(3)/13(4)	170000	120000
Generic /Informed consent, Art. 10 (1)/10c/13(1)/13c	140000	70000
Additional formulations and strengths applied at the same time	120000	50000
Annex I-applications except new formulations/strengths Veterinary : except change or addition of, food producing animals ¹⁾	110000	75000
Annex I ¹⁾ : New formulations/strengths (line extensions) Veterinary: Within the same target species	125000	55000
Annex I :Change or addition of, new food producing animal(s) ¹⁾		85000
Change or addition of, new non- food producing animal(s) ¹⁾		80000
Marketing Authorisation Application -traditional herbal	85000	

medicinal products, with monography		
-------------------------------------	--	--

For variation of Marketing Authorisations – see the part covering MRP

DCP where Norway is CMS		
	Human	Veterinary
Complete dossier/well-established use/fixed combinations, Art. 8(3)/10a/10b/12,3/13a/13b	210000	55000
Hybrid and biosimilar, Art. 10(3)/10(4)/13(3)/13(4)	160000	55000
Generic /Informed consent, Art. 10 (1)/10c/13(1)/13c	160000	55000
Additional formulations and strengths applied at the same time	100000	50000
Annex I-applications except new formulations/strengths Veterinary : except change or addition of, food producing animals ¹⁾	100000	50000
Annex I ¹⁾ : New formulations/strengths (line extensions) Veterinary: Within the same target species	100000	50000
Annex I :Change or addition of new food producing animal(s) ¹⁾		60000
Change or addition of, new non- food producing animal(s) ¹⁾		40000
Marketing Authorisation Application -traditional herbal medicinal products, with monography	20000	

For other variations see the parts covering MRP

Please note:

For grouped variations, according to Variation Regulation EC 1234/2008, the fee will be equal to the sum of each variation applicable for a fee.

Marketing Authorisations issued without national Product Information will also be applicable for a fee

Type IA and Type IB variations without changes to the SmPC, Patient Information Leaflet and labeling will not be charged

For products intended for MUMS (Minor Use/Minor Species) there is a 50% reduction in the fee MUMS-status must be clarified with the Norwegian Medicines Agency before submission.

Footnotes	
-----------	--

1)	Annex I to Variation Regulation nr EC 1234/2008
2)	For variation including several formulations and strengths of the same product one fee is invoiced.
3)	Variations leading to other consequential variations is invoiced as one.
4)	Applicable for each Marketing Authorisation number
5)	Applicable per procedure/agreement. Non- refundable
6)	One fee per chargeable variations (independent of the number of products included in the worksharing)
7)	Not applicable for linguistic changes, text being moved or information on limited documentation on the use in children etc. Those are other variations Type II
8)	Applicable independent of legal basis for submission
9)	Only applicable to minor variations not accompanied by any documentation. The fee is charged per part of the SmPC , e.g. If there is several linguistic changes in 4.1 , 4.1 and 5.1 – this is regarded as three linguistic variations. If no other variations is submitted the minimum fee is 5000,-

Updated:2012.06.08